Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jerusalem Pharmaceutical Co's EBIT per Share for the
three
months ended in Mar. 2026 was $0.08.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.37.
During the past 12 months, the average EBIT per Share Growth Rate of Jerusalem Pharmaceutical Co was 70.90% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 11.40% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 16.30% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 12.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Jerusalem Pharmaceutical Co's EBIT per Share or its related term are showing as below:
XPAE:JPH'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -64.5 Med: 11.45 Max: 44.2
Current: 11.4
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Jerusalem Pharmaceutical Co was 44.20% per year. The lowest was -64.50% per year. And the median was 11.45% per year.
XPAE:JPH's 3-Year EBIT Growth Rate is ranked better than 56.53% of 812
companies
in the Drug Manufacturers industry
Industry Median: 7.5
vs XPAE:JPH: 11.40
Jerusalem Pharmaceutical Co (XPAE:JPH) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Jerusalem Pharmaceutical Co EBIT per Share Related Terms
Jerusalem Pharmaceutical Co EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.37
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jerusalem Pharmaceutical Co (XPAE:JPH) has a EBIT per Share of $0.37 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Jerusalem Pharmaceutical Co and its competitors. According to the industry distribution chart, Jerusalem Pharmaceutical Co ranks #353 out of 812 companies in the Drug Manufacturers industry, placing it in the top 43.5%.
Is Jerusalem Pharmaceutical Co's EBIT per Share too high?
Jerusalem Pharmaceutical Co's current EBIT per Share is $0.37. The Drug Manufacturers industry median EBIT per Share is 7.50. Jerusalem Pharmaceutical Co's value of $0.37 is 95.1% below this industry median. Based on the distribution chart, Jerusalem Pharmaceutical Co ranks #353 out of 812 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Jerusalem Pharmaceutical Co has a GF Score™ of 82/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jerusalem Pharmaceutical Co's EBIT per Share compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Jerusalem Pharmaceutical Co ranks #353 out of 812 companies for EBIT per Share. This puts Jerusalem Pharmaceutical Co in the upper half of its industry. The industry median EBIT per Share is 7.50. Jerusalem Pharmaceutical Co's value of $0.37 is 95.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.50, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jerusalem Pharmaceutical Co's current EBIT per Share of $0.37 is 95.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Jerusalem Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jerusalem Pharmaceutical Co's current EBIT per Share is $0.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jerusalem Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Jerusalem Pharmaceutical Co (XPAE:JPH) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.41, compared to a current price of $3.57 — trading 48.1% above its estimated fair value. The current EBIT per Share is $0.37 and 95.1% below the Drug Manufacturers industry median of 7.50. Jerusalem Pharmaceutical Co's overall GF Score™ is 82/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Jerusalem Pharmaceutical Co (XPAE:JPH), the current EBIT per Share is $0.37 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jerusalem Pharmaceutical Co (XPAE:JPH) Overvalued in 2026?
Based on GuruFocus' analysis, Jerusalem Pharmaceutical Co stock appears to be overvalued.
The current stock price of $3.57 is trading 48.1% above its estimated GF Value™ of $2.41.
GuruFocus considers Jerusalem Pharmaceutical Co to be Significantly Overvalued.
Key valuation signals for XPAE:JPH:
EBIT per Share: $0.37
GF Value™: $2.41 vs. price of $3.57 (48.1% above fair value)
Industry Position: 95.1% below the Drug Manufacturers median (#353 of 812)
No single metric tells the full story. See the XPAE:JPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jerusalem Pharmaceutical Co is engaged in developing, manufacturing and marketing of human pharmaceuticals products. It also produces detergent, cosmetic, personal and home care products, veterinary and agricultural products. The company operates in Jordan, Algeria, the Middle East, and North Africa Region. Its product portfolio contains more than 300 pharmaceutical products in various dosage forms including tablets, capsules, sterile injectables, powders for suspensions, suspensions, syrups, powders, suppositories, ovules, creams, ointments, as well as ear and nose drops and solutions.
82GF Score
Get the complete analysis for XPAE:JPH
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAE:JPH has been successfully added to your 
